TY - JOUR
T1 - Pharmacologic evaluation of orally administered antibiotics in infants and children
T2 - Effect of feeding on bioavailability
AU - McCracken, G. H.
AU - Ginsburg, C. M.
AU - Clahsen, J. C.
AU - Thomas, M. L.
PY - 1978/12/1
Y1 - 1978/12/1
N2 - The clinical pharmacology of orally administered antibiotics was investigated in 106 infants and children. The antibiotic suspensions studied were ampicillin, cephalexin, erythromycin estolate, erythromycin ethylsuccinate, penicillin G, and penicillin V. The feeding status of the patients was evaluated in relation to the concentrations of drugs in serum, saliva, and tears. Peak concentrations and area-under-the-curve values of cephalexin, penicillin V, and penicillin G were reduced 40% to 60% in patients given milk and drug concurrently. Absorption was enhanced when erythromycin ethylsuccinate was given with milk. After administration of both erythromycin formulations, penicillin V and ampicillin, salivary concentrations exceeded the minimal inhibitory concentrations for most pneumococci and group A streptococci and for many meningococci. The clinical implications of these pharmacokinetic data are discussed.
AB - The clinical pharmacology of orally administered antibiotics was investigated in 106 infants and children. The antibiotic suspensions studied were ampicillin, cephalexin, erythromycin estolate, erythromycin ethylsuccinate, penicillin G, and penicillin V. The feeding status of the patients was evaluated in relation to the concentrations of drugs in serum, saliva, and tears. Peak concentrations and area-under-the-curve values of cephalexin, penicillin V, and penicillin G were reduced 40% to 60% in patients given milk and drug concurrently. Absorption was enhanced when erythromycin ethylsuccinate was given with milk. After administration of both erythromycin formulations, penicillin V and ampicillin, salivary concentrations exceeded the minimal inhibitory concentrations for most pneumococci and group A streptococci and for many meningococci. The clinical implications of these pharmacokinetic data are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0018136963&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018136963&partnerID=8YFLogxK
M3 - Article
C2 - 581516
AN - SCOPUS:0018136963
SN - 0031-4005
VL - 62
SP - 738
EP - 743
JO - Pediatrics
JF - Pediatrics
IS - 5
ER -